CP5V

Overview

CP5V is a Cdc20 PROTAC degrader with a DC 50 of 1.6 μM and a K d value of 12.4 μM. CP5V couples Cdc20 with the VHL/VBC complex, triggering its ubiquitination and proteasomal degradation, thereby reducing the protein levels of Cdc20 and securin . CP5V induces mitotic arrest, inhibits cell proliferation, resensitizes Paclitaxel-resistant breast cancer cells, and suppresses breast tumor progression in xenograft models. CP5V inhibits excessive proliferation and induces apoptosis in pulmonary arterial hypertension smooth muscle cells and fibroblasts. CP5V can be used in studies related to breast cancer and pulmonary arterial hypertension. (Pink: Cdc20 ligand ( HY-130841 ); Blue: VHL ligand ( HY-125845 ); Black: linker ( HY-116006 )).

Application

Products | Products > Disease Areas > Pulmonary Disease | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Pulmonary Hypertension | Products > Disease Areas > Cancer | Products > Disease Areas > Respiratory Disease | Products > Signaling Pathways > PROTAC | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cardiovascular Disease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > PROTACs | Products > Signaling Pathways > APC | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-130257
• CAS No.: 2509359-75-3
• Molecular Formula: C46H66Cl3N9O12S
• Molecular Weight: 1075.49
• Purity: 99.31%
• Storage: -20°C, stored under nitrogen * In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
• Solubility: ≥ 3.75 mg/mL (3.49 mM); Clear solution
• Availability: In-stock

Source

Original product source